Endo International — Corporate Update (December 2022)
6 slides from Endo International's corporate update, Dec 6, 2022
Slide 1: Qwo Update December 2022
Exhibit 99.2 Qwo Update December 2022 Confidential Cleansing Material endo.com
Slide 2: Disclaimer
Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources and is subject in all respects to the confidentiality agreement you have executed with the Company. All communications or
Slide 3: Executive Summary
Executive Summary ► The unfavorable perception of intense bruising following initial treatment and the risk of prolonged skin discoloration has created a significant and sustained hesitancy in QWO utilization in the market. ► A number of commercial and medical initiatives were launched over the last
Slide 4: APHRODITE-1 study results
APHRODITE-1 study results ► APHRODITE study primary endpoint is severity of bruising at days 3 to 5 following initial injection as this is the most important market concern that needs to be addressed. ‒ Secondary Endpoint – bruising resolution assessment at day 10 to 14 ‒ Efficacy assessment – day 9
Slide 5: We expect to realize $50-60M in total annual run rate cost savings
We expect to realize $50-60M in total annual run rate cost savings $ millions 2023 and Cash Savings [a],[b] 2022 Thereafter ▪ The level of QWO utilization will be Cost of sales (fixed only) $ - $ 5-10 significantly constrained due to the inability to effectively address the negative Operating expens
Slide 6: Next Steps
Next Steps Element Key Activity Tentative Date ▪ Consultations with advisors to (i) the 1L group, (ii) the cross-holder group, (iii) the committees and (iv) the future claimants’ w/o November 28 representative Chapter 11 ▪ 1L group consent December 5 or 6 ▪ Bankruptcy court approval January 19 [a] ▪
Endo International — Corporate Update (December 2022) on 6ix